Handelsbanken Fonder Ab Uni Qure N.V. Transaction History

Handelsbanken Fonder Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$13.15 - $20.45 $21,040 - $32,720	-1,600 Reduced 13.56%	10,200 $190,000
Q3 2021 Nov 10, 2021	BUY	$26.01 - $38.22 $109,242 - $160,524	4,200 Added 55.26%	11,800 $378,000
Q2 2021 Aug 03, 2021	BUY	$29.97 - $37.17 $38,961 - $48,321	1,300 Added 20.63%	7,600 $234,000
Q2 2020 Aug 26, 2020	BUY	$45.06 - $67.74 $283,878 - $426,761	6,300 New	6,300 $284,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.